The FDA has asked an outside panel of cardiac experts to review the effectiveness of Thoratec Corp.'s HeartMate II, a mechanical heart pump designed for heart failure patients awaiting transplants, before granting its approval. Analysts expect HeartMate II to receive a favorable review despite not reaching a key effectiveness goal in a company study.

Full Story:

Related Summaries